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Background: Cytogenetic and gene expression analyses in head and neck squamous cell carcinomas (HNSCC) have
allowed identification of genomic aberrations that may contribute to cancer pathophysiology. Nevertheless, the
molecular consequences of numerous genetic alterations still remain unclear.
Methods: To identify novel genes implicated in HNSCC pathogenesis, we analyzed the genomic alterations present
in five HNSCC-derived cell lines by array CGH, and compared high level focal gene amplifications with gene
expression levels to identify genes whose expression is directly impacted by these genetic events. Next, we
knocked down TRPC6, one of the most highly amplified and over-expressed genes, to characterize the biological
roles of TRPC6 in carcinogenesis. Finally, real time PCR was performed to determine TRPC6 gene dosage and mRNA
levels in normal mucosa and human HNSCC tissues.
Results: The data showed that the HNSCC-derived cell lines carry most of the recurrent genomic abnormalities
previously described in primary tumors. High-level genomic amplifications were found at four chromosomal sites
(11q21-q22.2, 18p11.31-p11.21, 19p13.2-p13.13, and 21q11) with associated gene expression changes in selective
candidate genes suggesting that they may play an important role in the malignant behavior of HNSCC. One of the
most dramatic alterations of gene transcription involved the TRPC6 gene (located at 11q21-q22.2) which has been
recently implicated in tumour invasiveness. siRNA-induced knockdown of TRPC6 expression in HNSCC-derived cells
dramatically inhibited HNSCC-cell invasion but did not significantly alter cell proliferation. Importantly, amplification
and concomitant overexpression of TRPC6 was also found in HNSCC tumour samples.
Conclusions: Altogether, these data show that TRPC6 is likely to be a target for 11q21–22.2 amplification that
confers enhanced invasive behavior to HNSCC cells. Therefore, TRPC6 may be a promising therapeutic target in the
treatment of HNSCC.
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The broad application of cytogenetic and molecular gen-
etics methods has led to the identification of tumor-
associated chromosomal regions substantial for the
tumorigenesis and progression of head and neck squa-
mous cell carcinomas (HNSCC) [1-3]. Comprehensive
analysis of recurrent amplified chromosomal regions has
allowed identification of oncogenes and other cancer-
related gene such as EMS1, CCND1, PPFIA1, TAOS1
(11q13), LOXL4 (10q24), PAK4 (19q13), and HIF1A
(14q23-q24) which have been associated with different
clinical behaviors [4-10]. Therefore, associations of
high-level genomic amplifications with altered gene ex-
pression and functional analysis of the affected genes
represents an excellent approach to identify novel genes
involved in tumor progression and carcinogenesis.
Here, we compared the genome-wide DNA copy num-
ber alterations present in five HNSCC-derived cell lines
with those previously reported in tumour tissues. Re-
markably, our data showed that the cell lines analyzed
here resemble most of the important genomic alterations
previously described in primary HNSCC. It also revealed
the presence of several regions with high level focal ampli-
fications (11q21-22.2, 18p11.31-p11.21, 19p13.2-p13.13,
and 21q11) that have been previously identified in
HNSCC [1,11].
Although rarely detected in solid tumors, high level
amplification at 11q22-q23 has been described not only
in HNSCC [12,13] but in many malignancies including
glioblastomas, renal cell carcinomas, sarcomas, and
cervical, lung and pancreatic cancers [14-19] thus
suggesting that this region may harbor gene(s) that,
when amplified, have an active role in tumorigenesis
and/or cancer progression. YAP gene has been identified
as a candidate target gene in 11q22 amplicon in several
human cancers [20-22]. However, to date, no specific
genes have been proposed as targets in HNSCC.
In the present report, we performed gene expression
analysis of the amplified genes in each amplicon identi-
fied in HNSCC-derived cell lines what allowed the iden-
tification of 12 novel genes with potential implications
in HNSCC biology. One of the most dramatically ampli-
fied and overexpressed gene identified here is TRPC6, a
member of the transient receptor potential (TRPC) sub-
family, located at 11q22.1. This novel genetic change
was also identified in primary HNSCC-tumour samples.
Remarkably, recent studies have revealed that TRPC6
has an essential role in glioma growth, invasion, and angio-
genesis [23,24]. We show here that TRPC6 overexpression
confers enhanced invasive behavior to HNSCC cells.
Therefore, TRPC6 may have an essential role in the
development of the aggressive phenotype of HNSCC
and may be a promising therapeutic target in the
treatment of HNSCC.Methods
Cell lines
The five established human HNSCC cell lines used in this
study were kindly provided by Dr. Grenman [25]. Cell
lines were derived from primary tumors located at the oral
cavity (SCC2 and SCC40 cell lines) and larynx (SCC29,
SCC38 and SCC42B cell lines). Cells were grown in
Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum, 100 units/ml penicillin, 200 μg/ml
streptomycin, 2 mM L-glutamine, 20 mM Hepes pH 7.3
and 100 μM non-essential aminoacids. All cells were
maintained at 37°C in 5% CO2.
Tissue samples
Surgical tissue specimens from 24 patients with HNSCC
were obtained, following institutional review board
guidelines, from the Hospital Universitario Central de
Asturias and Hospital General Universitario de Valencia.
All the procedures utilized in this study are in agreement
with the 1975 Helsinki Declaration. Informed consent
was obtained from each patient. All the patients in-
cluded in our study underwent surgical resection of their
tumor and bilateral neck dissection (functional or radical
based on surgical findings). All of them had a single pri-
mary tumor; none had undergone treatment prior to
surgery, and had microscopically clear surgical margins.
A portion of the surgical tissue specimen was sharply ex-
cised, placed in sterile tubes, and stored at −80°C in
RNAlater (Ambion) for DNA and RNA analysis. Clinic-
ally normal adjacent mucosa and normal mucosa from
non-cancer patients were also collected. All patients
were habitual tobacco and alcohol consumers.
DNA and RNA isolation
Genomic DNA was isolated using the QIAmp DNA Mini
kit (Qiagen, Inc., Chatsworth, CA) and subsequently
treated with RNase A (1unit/mL) at 37°C for 5 minutes.
Total RNA was isolated from HNSCC cell lines and
tumour tissues with Nucleospin RNA II (Macherey-Nagel,
Easton, PA) following the manufacturer’s instructions with
the addition of an extra acid phenol/chloroform extraction
followed by RNA precipitation.
Array-CGH
Arrays-CGH were performed as described by van den
Ijssel et al. [26]. Briefly, tumour cell lines and reference
DNAs (pooled from 10 different donors) were differently
labelled by random priming. Three hundred ng test and
reference DNA were hybridized to an array containing
approximately 30,000 DNA oligos spread across the
whole genome printed on Codelink activated slides
(Amersham Biosciences, Barcelona, Spain). This array
contained 29,134 oligos covering 28,830 unique genes.
Hybridization and washing took place for two nights in a
Bernaldo de Quirós et al. BMC Cancer 2013, 13:116 Page 3 of 11
http://www.biomedcentral.com/1471-2407/13/116specialized hybridization chamber (GeneTAC/HybArray12
hybstation; Genomic Solutions/Perkin Elmer). Images were
acquired using a Microarray Scanner G2505B (Agilent
Technologies). Analysis and data extraction were quantified
by BlueFuse (BlueGnome, Cambridge, UK). Gains were
defined as at least two neighbouring oligonucleotides with
deviations of 0.2 or more from log2 ratio = 0.0. High-level
amplification was considered when at least two neigh-
bouring clones reached a log2 ratio of 1.0 or higher.
qPCR
Real-time PCR was done in an ABI Prism 7500 Real Time
PCR System (Applied Biosystems, Foster City, CA) using
Power SYBR Green PCR Master mix (Applied Biosystems)
and the thermocycler conditions recommended by the
manufacturer. Primers, designed using the computer pro-
gram Primer Express (Applied Biosystems), were as de-
scribed in Table 1.
To perform mRNA quantifications, first-strand cDNA
was synthesized from 2 μg of total RNA using the
Superscript first-strand synthesis system for reverse tran-
scriptase (Invitrogen, Carlsbad, CA) with random primers
and oligodT according to the manufacturer’s directions.
Cyclophilin was used to normalize for RNA input amounts
and to perform relative quantification. To perform genomic
DNA amplification, tyrosine hydroxylase gene was used to
normalize for DNA input amounts and to perform relative
quantification. Melting curve analysis showed a single sharp
peak with the expected Tm for all samples and genes tes-
ted. Relative quantities were obtained using the 2–ΔΔCt
method [27].
Western blot
Protein extracts were obtained from SCC42B cells at 70%
to 80% confluence by scraping on ice in lysis buffer
containing 50 mmol/l HEPES (pH 7.9), 250 mmol/l NaCl,
5 mmol/l EDTA, 0.2% NP40, 10% glycerol, and protease in-
hibitors (0.5 mmol/l phenylmethylsulfonyl fluoride, 1 μg/ml
aprotinin, 10 μg/ml leupeptin and 1 mmol/l Na3VO4).
Equal amounts of proteins were fractionated on SDS-PAGE
and transferred to PVDF membranes. Membranes were
probed with anti-TRPC6 antibody (Abcam) or anti-β-actin
(Sigma-Aldrich) at 1:100 and 1:5000 dilutions, respectively.
Bound antibodies were detected using Enhanced Chemilu-
minescence Reagent (Amersham Pharmacia Biotech) accor-
ding to the protocol of the manufacturer.
siRNA treatment
siRNA duplex oligonucleotides (ON-TARGETplus
SMARTpool Human TRPC6) were purchased from
Dharmacon Research (Lafayette, CO). siCONTROL Non-
targeting pool (Dharmacon) were used as control siRNA.
SCC42B cells were transfected with 35 pmol/ml siRNAs
using Lipofectamine 2000. TRPC6 mRNA analyses revealeda substantial inhibition (more than 60–70%) of TRPC6 ex-
pression 48–72 hours after transfection. The transfected
cells were used for subsequent experiments within that
interval of time.
Wound healing assay
Cells were grown to confluence in 35-mm tissue culture
dishes. Cell monolayers were wounded using a micropip-
ette tip, and floating cells were removed by extensive
washing with DMEM. Photographs of the wounded area
were taken immediately after making the scratch (0 h
time point) and after 8 h using a Leica DMIL micro-
scope to measure the migration rate of cells into the
wounded area. At least 15 different fields were randomly
chosen across the wound length. For the analysis of the
differential cell migration capacity of SCC38, SCC40,
and SCC42B cells, the rate of front migration of cell
monolayers was analyzed in an AxioObserver.Z1 micro-
scope (Zeiss), equipped with an incubation module, by
taking pictures at 0 h and 8 h using an EC Plan-
Neofluor 10x/0.30 Ph1 objective.
Matrigel invasion assays
In vitro invasion assays were performed by using a 24-
well invasion chamber coated with Matrigel (Becton
Dickinson). Cells were trypsinized, washed with PBS,
suspended in DMEM containing 5% BSA, and plated in
the invasion chamber (3 x 104 cells per well). The lower
chambers were filled with DMEM containing 5% BSA
with 10% FBS. After 24 h, the cells remaining in the
upper chamber were removed by scraping, whereas the
cells that invaded through Matrigel were fixed and
stained by using 0.5% Crystal Violet in methanol. All in-
vading cells were counted by microscopic visualization.
All analyses were performed in triplicate.
MTS-based cell proliferation assay
MTS assays were performed using CellTiter 96 Cell
Non-Radioactive Proliferation Assay following the pro-
tocol recommended by the manufacturer (Promega,
Madison, WI). Briefly, 1000 cells were seeded in each
well of 96-well plates, and allowed to growth for 48, 72 or
96 hours. MTS assay was performed at each time point.
Results and discussion
Array CGH analysis of HNSCC-derived cell lines
Array CGH was used to characterize genome-wide DNA
copy number alterations in five HNSCC-derived cell
lines. Visual inspection of the array CGH profiles re-
vealed the presence of an overall pattern that is broadly
consistent with the literature in HNSCC (a summary of
the chromosomal aberrations is shown in Table 2). Some
degree of gain and/or loss was detected in every cell line.
The data predicted frequent copy number gains (present
Table 1 Oligonucleotides used for real time PCR
Gene Oligonucleotides
JRKL Forward: 50CGCGATAGTCAGGGAGCTGT 30
Reverse: 50GGGTTGGCTGGCAAATAGAC 30
CNTN5 Forward: 50CACCCCATCTCGAATGATCC 30
Reverse: 50GGTGCTGTCTTCGGAACTGC 30
AD031 Forward: 50TCTCCTGTTGATTCGCAGATGT 30
Reverse: 50 TTGAGACCAGTTGATGAATACTCGA 30
PGR Forward: 50AACTTCTTGATAACTTGCATGATCTTG 30
Reverse: 50AGCAGTACAGATGAAGTTGTTTGACA 30
TRPC6 Forward: 50TTCTCATGGATGGAGATGCTCA 30
Reverse: 50CCATATCATGCCTATTACCCAGGA30
YAP1 Forward: 50GACTTCCTGAACAGTGTGGATGAG 30
Reverse: 50TGCTTTGGTTGATAGTATCACCTGTAT 30
BIRC3 Forward: 50CATCCGTCAAGTTCAAGCCA 30
Reverse: 50GATAGCAGCTGTTCAAGTAGATGAGG 30
PORIMIN Forward: 50TGCTTCATCAGTAACAATCACAACA 30
Reverse: 50CCTTTCTTTGCTTCAGAATGCAT 30
MMP7 Forward: 50CCAGGATGATATTAAAGGCATTCA 30
Reverse: 50TGAATTACTTCTCTTTCCATATAGTTTCTGA 30
MMP20 Forward: 50CTGCTCTTCAAGGACCGGATT 30
Reverse: 50TGTCCGCAAGTGAACCTGC 30
MMP27 Forward: 50GCATTTGGTGCTGGAGGTTT 30
Reverse: 50ACCCTTTGTCCATGGTTTGG 30
MMP8 Forward: 50AGTTGATGCAGTTTTCCAGCAA 30
Reverse: 50GGTCCACTGAAGACATGGAAGAA 30
MMP10 Forward: 50TGCATCAGGCACCAATTTATTC 30
Reverse: 50GAGTGGCCAAGTTCATGAGCA 30
MMP1 Forward: 50TGGACCAACAATTTCAGAGAGTACA 30
Reverse: 50TTCATGAGCTGCAACACGATG 30
MMP3 Forward: 50TCTTTGTAGAGGACAAATACTGGAGATT 30
Reverse: 50CCATGGAATTTCTCTTCTCATCAA 30
MMP12 Forward: 50CGATGAGGACGAATTCTGGAC 30
Reverse: 50CAGTGAGGAACAAGTGGTGCC 30
MMP13 Forward: 50GCCATTACCAGTCTCCGAGG 30
Reverse: 50GCAGGCGCCAGAAGAATCT 30
RNMT Forward: 50GTTCCTGAATTCTTGGTCTATTTTCC 30
Reverse: 50CTTCTTTGCCATTTCATTTAGCAAT 30
MC5R Forward: 50TTGGATCTCAACCTGAATGCC 30
Reverse: 50TTGACATTGGGTCCTGAAAGG 30
MC2R Forward: 50CCTTCTCATTCATTTTGCCCA 30
Reverse: 50TCCCAATCACCTTCAGCTCG 30
ZNF443 Forward: 50GAACCTGGATTGTGTAGTAATGAAATG 30
Reverse: 50TGATCTTCAATGTTCTGGTCTTTCC 30
MAN2B1 Forward: 50GCTCAAAACCGTGGACCAGT 30
Reverse: 50GGCGTGCTGGATGTCATTCT 30
Table 1 Oligonucleotides used for real time PCR
(Continued)
JUNB Forward: 50AAACTCCTGAAACCGAGCCTG 30
Reverse: 50CGCTTTGAGACTCCGGTAGG 30
STCH Forward: 50AACCCGAGCAATGTCTGGAA 30
Reverse: 50TGATTGAAGTCCTGTCCTCCAA 30
NRIP1 Forward: 50GGGATCAGGTACTGCCGTTG 30
Reverse: 50TCCTCTTCATTATGCCCAGCA 30
CYPA Forward: 50CATCTGCACTGCCAGACTGA 30
Reverse: 50TTGCCAAACACCACATGCTT 30
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5p, 7p, 8q, 9q, 11q, 14q, 18p, and 20q; and losses for 3p,
9p, 11q, and 18q. These copy number alterations, re-
vealed through CGH-array, had been previously detected
with conventional metaphase CGH analysis in HNSCC
primary samples [1,28]. High-level amplifications were
detected at four chromosomal sites including 11q21-q22.2,
18p11.31-p11.21, 19p13.2-p13.13, and 21q11 (see Figure 1).
Gains encompassing these genomic regions have been
described in previous reports [11,12,29,30]. In addition to
known regions, our CGH-array analysis disclosed alte-
rations that had never been reported using conventional
techniques, such as small gains in 4p12, 13q12, 21q21,
and losses in 22q13 (Table 3).
In general, the array CGH data showed that the recur-
rent genome aberrations described in primary HNSCC
tissues are well preserved in the cell lines analyzed here.
It also indicates that these cell lines have not accumu-
lated substantial novel recurrent aberrations during ex-
tended culture. These data, together with our previous
molecular and functional studies [31,32], suggest that
analysis of genomic aberrations in the HNSCC-derived
cell lines used here might be a useful approach to iden-
tify tumor-associated chromosomal regions substantial
for the tumorigenesis and progression of HNSCC.
Impact of focal high-level amplifications on gene
expression
To gain some insights into the role of genomic aberra-
tions in HNSCC pathophysiology, we focused in focal
amplification events for which it may be easier to pin-
point target genes involved in the pathogenesis of
HNSCC.
The present analysis allowed narrowing down and de-
lineating the boundaries of high-level amplification
events. Boundaries from the p-telomere span from 95 to
102 Mb (11q21-q22.2), 3,44 to 16,81 Mb (18p11.31-
p11.21), 11 to13 Mb (19p13.2-p13.13), and 14,1 to
15,3 Mb (21q11). These are relatively small genomic seg-
ments containing 20 or fewer genes (listed in Figure 1)
Table 2 Most frequently reported chromosomal gains and losses present in HNSCC-derived cell lines
Chro Region Size
(Mb)
Frequency Known proto-oncogenes Cell line with minimal region of
change
Chromosomal gains
1p 1p32.1-p21.1 47,25 2/5 - SCC40
3q 3q13.2-qter 84,9 4/5 BCL6, EIF4A2, EVI1, GMPS, LPP, MDS1, MLF1, PI3K3CA, RPN1,
TFRC, ZNF9
SCC2
5p 5pter-p12 45 3/5 LIFR SCC38
6q 6q16.3-q23.3 38,82 1/5 FOXOA3, GOPC, ROS1, STL SCC40
7p 7pter-p14.3 32 3/5 ETV1, HOXA9, HOXA11, HOXA13, HNRPA2B1, JAZF1, PMS2 SCC29
7q 7q21.13-q31.1 22,87 1/5 AKAP9, CDK6 SCC2
8q 8q21.1-q24.22 64,6 5/5 COX6C, EXT1, MYC, NBS1 SCC29
9p 9p21.2-p13.2 12,28 2/5 PAX5, FANCG SCC29
9q 9q21.33-
q34.11
43 4/5 FANCC, NR4A3, OMD, PTCH1, SYK, TAL2, XPA SCC29
11q 11q12.2-q12.3 1,9 4/5 - SCC42B
11q13.2-q22.2 33,1 4/5 PRAD1, NUMA1, PICAM, MAML2, BIRC3 SCC40
11q23.3 0,20 3/5 SCC40
DDX6
14q 14q23.1-q24.2 13,23 1/5 GPHN, RAD51L1 SCC2
14q31.1 0,72 3/5 TSHR SCC2
18p 18p11.31-
p11.21
13.37 4/5 - SCC40
19p 19p13.2-
p13.13
1,64 1/5 LYL1 SCC42B
20q 20q11.21-
q11.23
4,86 3/5 - SCC42B
Chromosomal losses
1p 1p13.2-p12 7,35 2/5 NRAS, TRIM33 SCC29, SCC40
3p 3p23-p22.3 2,5 4/5 MLH1 SCC2
5q 5q11.1-q12.3 13,11 2/5 - SCC29, 38
8p 8pter-q11.21 47,1 2/5 PCM1, FGFR1, WRN, WHSC1L1 SCC40
9p 9p21.3 2,61 3/3 CDKN2A, CDKN2B, MLLT3 SCC29
10p 10pter-p11.21 37,35 2/5 COPEB, MLLT10, SH3BP1 SCC2, SCC40
11q 11q22.3-qter 15,29 3/5 ATM, CBL, DDX10, PAFAH1B2, POU2AF1, SDHD, ZNF145, FLI1,
PRO1073
SCC42B
18q 18q21.1-qter 29,97 3/5 BCL2, FVT1, SMAD4, MALT1 SCC40
22q 22q11.21 1,03 2/5 BCR, CLTCL1, PNUTL1, SMARCB1 SCC29
22q12.1-q12.2 1,96 2/5 SCC40
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amplification. These amplicons do not contain well-
established oncogenes in HNSCC. To identify putative
driver genes in these genomic regions, we compared the
expression levels of candidate genes mapping in the
amplicons with their DNA copy number status. Figure 1
illustrates genome-wide copy number plots of the gene
amplifications and the gene expression data.
Interestingly, a high degree of correlation between DNA
and mRNA levels was found for most of the genes selectedat 11q, 18p, 19p, and 21q amplicons. This is in agreement
with previous studies showing that amplification has a
strong impact on transcription levels [33-35]. Expression
of RNMT, MC5R, and MC2R genes at 18p11.31-p11.21
amplicon was significantly up-regulated in SCC40 cells
that had shown high-level amplification at that locus,
compared with cell lines without gene amplification
(p < 0,0001) (Figure 1B). Similarly, the expression levels of
the STCH and NRIP1 genes at 21q11 were significantly
higher in SCC29 cells, which harbored amplification at
AB
C
D
Figure 1 Genome-wide copy number plots of gene amplifications and relative mRNA expression data in HNSCC-derived cell lines. Left
panels show the profiles as normalized log2 signal intensity ratios of each spot on the array to the genomic position at chromosome 11 (A),
chromosome 18 (B), chromosome 19 (C) from p-to t-telomere, and chromosome 21 (D) from chromosomal band 11p11.2 to t-telomere. Right
panels show the relative mRNA levels of the indicated genes in the HNSCC-derived cell lines. Total RNA was extracted from HNSCC-derived cell
lines grown to 80–90% confluence. mRNA levels were analyzed by RT-qPCR.
Table 3 Non previously identified altered chromosomal regions
Chro Alteration Region Size (Mb) Frequency Known proto-oncogenes Cell line with minimal region of change
4 gain 4p12 7,08 1/5 TEC SCC29
13 gain 13q12.12-q12.3 5,49 2/5 CDX2, FLT3 SCC29, SCC40
21 amplification 21q11 1,20 1/5 - SCC29
gain 21q21.1 1,36 5/5 - SCC29, SCC40
gain 21q21.3 4,59 2/5 - SCC29, SCC38
22 loss 22q13.2 0,62 5/5 - SCC2, SCC29
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Table 4 Relative TRPC6 DNA and mRNA levels in HNSCC
primary tumors
Tumor sample Genomic TRPC6 DNA levels* TRPC6 mRNA Levels*
7 T 5.70 1.7
8 T 0.67 1.2
11 T 2.01 2,85
12 T 1.60 1.38
13 T 3.90 1.9
14 T 0.60 0.56
17 T 2.00 1.01
21 T 3.00 5.77
23 T 1.27 7.5
25 T 1.27 1.05
26 T 1.75 5.91
27 T 1.55 1.84
32 T 2.60 1.7
33 T 1.40 9.53
95 T 0.37 1.46
110 T 1.60 1.38
112 T 2.90 4.14
124 T 0.80 2.87
127 T 0.86 1.76
141 T 3.59 19.02
143 T 0.60 1.03
147 T 0.60 0.16
154 T 1.40 0.41
155 T 0.61 0.16
*Values showing gene gain (#2) and increased mRNA levels (#1.7) are indicated
in bold.
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ation (p < 0,01) (Figure 1D). Amplification of the ZNF443,
andMAN2B1 genes at 19p13.2-p13.13, detected in SCC42B
cells, also correlated with higher expression at the mRNA
levels as compared with the other cell lines (p < 0,05)
(Figure 1C). However, quantification of the mRNA levels
of the JUNB proto-oncogene (19p13.2-p13.13) revealed
that SCC42B cells had similar levels of expression than
SCC29 cells, which did not show amplification of the
19p13.2-p13.3 locus. These data indicate that ZNF443
and/or MAN2B1 genes, but not JUNB, might be candi-
dates of the selection pressure for structural amplification
of the 19p13.2-p13.3 region, at least in SCC42B cells. In
general, any of the amplified and over-expressed genes
identified here (RNMT, MC5R, MC2R, ZNF443, MAN2B1,
NRIP1, and STCH) might be up-regulated in a DNA copy
number-dependent manner and could possibly contribute
to HNSCC pathogenesis. To our knowledge, no previous
evidence is available on the association of these genes in
HNSCC biology. Of all the genes analyzed here, only JUNB
has been previously found up-regulated at the mRNA and
protein level in HNSCC tumour tissues [36-39]. Our data
suggest that its over-expression is caused by mechanisms
other than gene amplification. Nevertheless, further studies
are required to demonstrate unequivocally whether an as-
sociation exists between the genetic and expression data in
tumour tissue samples.
With regard to the 11q21-q22.2 amplicon, recent studies
reported high copy number amplification at this locus in
HNSCC [12,13,30]. This region contains 18 known genes
harbouring two gene clusters, one with nine matrix
metalloproteinase (MMP) genes, and other with two
baculoviral IAP repeat-containing protein (BIRC) genes. Ex-
pression analysis of BIRC and MMP genes in the HNSCC-
derived cell lines showed no correlation between their
mRNA levels and DNA copy number status. In contrast,
expression of JRKL, AD031, TRPC6, (Figure 1A), YAP1 and
PORIMIN (data not shown) genes were significantly up-
regulated in SCC42B cells that had shown high-level ampli-
fication at that locus, compared with cell lines without gene
amplification (p < 0,01). Specifically, mRNA levels of JRKL,
AD031, TRPC6, YAP1, and PORIMIN were, respectively,
30, 50, 600, 10, and 8-fold higher in SCC42B cells than
in the other cell lines. mRNA expression of other candidate
genes at 11q21-q22.2 amplicon (CNTN5, PGR, and
MMP27) was not detected in any of the cell lines. These
data exclude CNTN5, PGR, MMP and BIRC genes and
point to any of the 5 amplified and over-expressed genes as
critical gene-amplification “driver/s”. Of them, only TRPC6
and YAP1 genes have been previously found deregulated
in several types of cancer. Amplification and mRNA up-
regulation of YAP1 has been previously described in several
cancers including HNSCC of the oral cavity [20,30,40], sar-
comas, meduloblatomas, and mesotheliomas [20,21,41,42].In addition, recent studies showed that over-expression
of YAP1 induces phenotypic alterations that are commonly
associated with potent transforming oncogenes [40,42-44].
TRPC6 is a member of the TRP family of Ca2+- and
Na+-permeable channels shown to be up-regulated in glio-
blastomas and breast, prostate, gastric, and oesophageal
cancer cells [23,45-48]. Our data revealed that this was the
most dramatically up-regulated gene in SCC42B cells.
However, to the best of our knowledge, up-regulation of
TRPC6 has not been previously identified in HNSCC.
TRPC6 gene is amplified and over-expressed in HNSCC-
tissue specimens
TRPC6 DNA and mRNA levels were analyzed in a panel
of 24 primary tumors (Table 4). Eight out of 24 tumor sam-
ples displayed increased gene copy number as compared
with a pool of DNA samples obtained from normal mucosa
of five healthy individuals. Analysis of TRPC6 mRNA levels
revealed that it was absent in normal mucosa from non-
cancer patients. Similarly, it was either absent or barely
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mors, and in 11/24 tumor samples. In contrast, 13 tumor
tissues displayed TRPC6 mRNA levels that were 1.7- to
19-fold above the highest level found in normal mucosa.
All but one tumor showing increased TRPC6 gene dosage
also harbored TRPC6 mRNA over-expression. These data
suggest that TRPC6 amplification may be responsible for
TRPC6 over-expression and is a candidate driver gene in
11q21-q22.2 amplicon that may play a role in HNSCC
pathophysiology.
Inhibition of TRPC6 expression does not induce changes
in SCC42B cell proliferation
Previous studies have shown that inhibition of TRPC6 ex-
pression results in decreased cell proliferation in cancer
cells [23,24,47,49,50]. To investigate the possible role of
TRPC6 on cell proliferation of HNSCC cells, MTS assays
and cell counting were performed in SCC42B cells express-
ing siRNA against TRPC6, and in their corresponding con-
trol cells. As shown in Figure 2, inhibition of TRPC6
expression did not affect significantly the cell growth rates.
Accordingly, the number of cells in each phase of the cell
cycle was similar in SCC42B cells transfected with TRPC6
siRNA versus control siRNA (data not shown). We did not0
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Figure 2 TRPC6 inhibition does not affect cell proliferation in SCC42B
(TRPC6i) 48 hours before MTS assay. (A and B) Reduction of TRPC6 mRNA (
quantified using RT–qPCR. The mean of relative expression to cyclophilin A
shown. (C) Cell growth was determined using a colorimetric MTS assay. Co
experiments. * p < 0.05 paired Student’s t test.find association between the proliferation rate of SCC cells
and the presence of TRPC6 gene amplification and over-
expression. SCC42B cells carrying 11q21-q22.2 amplifica-
tion proliferate more rapidly than SCC29 and SCC40 cells,
but they growth at similar rates than SCC38 and SCC2
cells (data not shown). These data show that, in the
tumour background examined here, TRPC6 is not import-
ant for cell proliferation.
Inhibition of TRPC6 expression impairs cell migration and
invasion
In addition to cell proliferation, Ca2+ signaling is known to
be involved in cell locomotion. It was therefore tempting
to speculate that SCC42B cells have a high migratory cap-
acity. Comparison of the cell migration behavior of
SCC38, SCC40 and SCC42B cells revealed that the migra-
tory potential of SCC42B cells, which express high levels
of TRPC6 and harbor 11q21-q22.2 amplification, was sig-
nificantly higher than that of SCC38 and SCC40 cells,
containing lower levels of TRPC6 mRNA and genomic
DNA (Figure 3A and B). This different phenotype may be
the result of different levels of TRPC6 gene expression or,
alternatively, could be caused by other gene(s)/protein(s)
structural or functional alterations in the cell linesCi
TRPC6i
100
50
Kd
TRPC6
-actin
Ci TRPC6i
B
cells. SCC42B cells were transfected with control (Ci) or TRPC6-siRNA
A) and protein (B) levels by siRNA treatment. Transcripts were
housekeeping gene of at least three independent experiments is
lumns, mean cell growth relative to control of three independent
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http://www.biomedcentral.com/1471-2407/13/116explored here. We therefore sought to determine whether
inhibition of TRPC6 expression by siRNAs affects cell mi-
gration in SCC42B cells. As shown in Figure 3D, knock
down of TRPC6 expression by siRNA resulted in a 36% de-
crease in cell migration as compared with cells transfected
with nonspecific siRNAs. SCC42B cells were also analyzed
for their invasive potential through a B1-mm Matrigel bar-
rier compared with cells transfected with TRPC6 siRNA.
The data revealed that invasion was dramatically inhibited
with TRPC6 siRNA expression showing a ~90% decrease in
invasiveness (Figure 3C and E).
Plasma membrane ion channels contribute to virtually all
basic cellular processes and are also involved in the malig-
nant phenotype of cancer cells by modulating different hall-
marks of cancer such as proliferation, cellular locomotion,
and tissue invasion. Specifically, the morphological and ad-
herence changes of metastatic cells involve Ca2+ signaling
supported by enhanced Ca2+ influx. Recently, TRPC6 has
emerged as an important player in the control of the ag-
gressive phenotype of glioblastoma cells [23]. Our analysisA B
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Figure 3 Inhibition of TRPC6 gene expression decreases cellular migr
in SCC38, SCC40 and SCC42B cells. The rate of front migration of cell mono
different fields were randomly chosen across the wound length. Values are
E) SCC42B cells treated with control (Ci) or TRPC6 siRNA (TRPC6i) were seed
The lower chamber was loaded with regular media supplemented with 10
top filter was scraped, and invading cells were fixed and stained. (C) Repre
All invading cells were counted under x10 magnification. Values are mean
triplicate. (D) Inhibition of TRPC6 expression in SCC42B cells attenuates cell
TRPC6- (TRPC6i) or control-siRNA (Ci). Values are mean of average ± s.d. fromof the functional significance of TRPC6 overexpression in
HNSCC showed that TRPC6 also modulates cell invasion
in HNSCC cells. This finding is of interest as it provides
the opportunity to therapeutically target TRPC6 to interfere
with Ca2+-dependent signaling involved in cell invasion.
Conclusions
In the present study, we report that TRPC6 (11q22) is
overexpressed in HNSCC, and provide new evidence that
increase in gene dosage is a novel mechanism to activate
TRPC6 expression in cancer. Increased TRPC6 mRNA and
gene dosage was detected in both, cell lines and tumor tis-
sues, revealing that this molecular alteration can be patho-
logically relevant in HNSCC. In addition, siRNA-induced
knockdown of TRPC6 expression in HNSCC-derived cells
dramatically inhibited HNSCC-cell invasion. Therefore,
TRPC6 is likely to be a target for amplification that confers
enhanced invasive behavior to HNSCC cells and, therefore,
may be a promising therapeutic target in the treatment of
HNSCC. These data provide the foundation for furtherCtrli TRPC6i
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ation and invasion. (A and B) Wound healing assays were performed
layers was analyzed by time-lapse video microscopy. At least 15
mean of average ± s.d. from three independent experiments. (C and
ed in serum-free media in the upper chamber of Matrigel transwells.
% fetal bovine serum and 5% BSA. After 24 h at 37°C in 5% CO2, the
sentative images captured with a 10 objective 24 h after seeding. (E)
of average ± s.d. from three independent experiments done in
migration. Wound healing assays were performed in cells treated with
three independent experiments.
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tumor tissues to determine whether it is crucial for tumor
development or progression.
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